Login / Signup

Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.

Pierre-François LaterrePeter PickkersGernot MarxXavier WitteboleFerhat MezianiThierry DugernierVincent HuberlantTobias SchuerholzBruno FrançoisJean-Baptiste LascarrouAlbertus BeishuizenHaikel OueslatiDamien ContouOscar HoitingJean-Claude LacheradeBenjamin ChoustermanJulien PottecherMichael BauerThomas GodetMahir KarakasJulie HelmsAndreas BergmannJens ZimmermannKathleen RichterOliver HartmannMelanie ParsAlexandre Mebazaanull null
Published in: Intensive care medicine (2021)
Overall, we successfully completed a randomized trial evaluating selecting patients for enrolment who had a disease-related biomarker. There were no overt signals of harm with using two doses of the adrenomedullin antibody adrecizumab; however, further randomized controlled trials are required to confirm efficacy and safety of this agent in septic shock patients.
Keyphrases